Skip to main content
NASDAQ:VRPX

Virpax Pharmaceuticals Competitors

Notice: Trading of Virpax Pharmaceuticals halted at 09:48 AM EST due to "LULD pause".
$4.11
+0.22 (+5.66 %)
(As of 05/17/2021 12:00 AM ET)
Add
Compare
Today's Range
$3.79
$4.73
50-Day Range
$3.85
$6.00
52-Week Range
$3.79
$8.24
Volume680,669 shs
Average Volume175,038 shs
Market Capitalization$20.32 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Virpax Pharmaceuticals (NASDAQ:VRPX) Vs. UPC, VRDN, IKT, VIRX, CUBT, and NLSP

Should you be buying VRPX stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to Virpax Pharmaceuticals, including Universe Pharmaceuticals (UPC), Viridian Therapeutics (VRDN), Inhibikase Therapeutics (IKT), Viracta Therapeutics (VIRX), Curative Biotechnology (CUBT), and NLS Pharmaceutics (NLSP).

Universe Pharmaceuticals (NYSE:UPC) and Virpax Pharmaceuticals (NASDAQ:VRPX) are both small-cap companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, earnings, risk and valuation.

Earnings and Valuation

This table compares Universe Pharmaceuticals and Virpax Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Universe PharmaceuticalsN/AN/AN/AN/AN/A
Virpax PharmaceuticalsN/AN/AN/AN/AN/A

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Universe Pharmaceuticals and Virpax Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Universe Pharmaceuticals0000N/A
Virpax Pharmaceuticals0000N/A

Profitability

This table compares Universe Pharmaceuticals and Virpax Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Universe PharmaceuticalsN/AN/AN/A
Virpax PharmaceuticalsN/AN/AN/A

Viridian Therapeutics (NASDAQ:VRDN) and Virpax Pharmaceuticals (NASDAQ:VRPX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, institutional ownership and analyst recommendations.

Profitability

This table compares Viridian Therapeutics and Virpax Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Viridian TherapeuticsN/AN/AN/A
Virpax PharmaceuticalsN/AN/AN/A

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Viridian Therapeutics and Virpax Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Viridian Therapeutics00203.00
Virpax Pharmaceuticals0000N/A

Viridian Therapeutics currently has a consensus price target of $34.00, suggesting a potential upside of 94.62%. Given Viridian Therapeutics' higher possible upside, equities research analysts clearly believe Viridian Therapeutics is more favorable than Virpax Pharmaceuticals.

Earnings & Valuation

This table compares Viridian Therapeutics and Virpax Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Viridian TherapeuticsN/AN/AN/AN/AN/A
Virpax PharmaceuticalsN/AN/AN/AN/AN/A

Summary

Viridian Therapeutics beats Virpax Pharmaceuticals on 2 of the 2 factors compared between the two stocks.

Virpax Pharmaceuticals (NASDAQ:VRPX) and Inhibikase Therapeutics (NYSE:IKT) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, valuation, analyst recommendations, profitability and earnings.

Profitability

This table compares Virpax Pharmaceuticals and Inhibikase Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Virpax PharmaceuticalsN/AN/AN/A
Inhibikase TherapeuticsN/AN/AN/A

Analyst Recommendations

This is a summary of recent recommendations and price targets for Virpax Pharmaceuticals and Inhibikase Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Virpax Pharmaceuticals0000N/A
Inhibikase Therapeutics00103.00

Earnings & Valuation

This table compares Virpax Pharmaceuticals and Inhibikase Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Virpax PharmaceuticalsN/AN/AN/AN/AN/A
Inhibikase TherapeuticsN/AN/AN/AN/AN/A

Summary

Inhibikase Therapeutics beats Virpax Pharmaceuticals on 1 of the 1 factors compared between the two stocks.

Virpax Pharmaceuticals (NASDAQ:VRPX) and Viracta Therapeutics (NASDAQ:VIRX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, profitability, valuation and institutional ownership.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Virpax Pharmaceuticals and Viracta Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Virpax Pharmaceuticals0000N/A
Viracta Therapeutics00403.00

Viracta Therapeutics has a consensus target price of $33.50, suggesting a potential upside of 308.04%. Given Viracta Therapeutics' higher probable upside, analysts plainly believe Viracta Therapeutics is more favorable than Virpax Pharmaceuticals.

Profitability

This table compares Virpax Pharmaceuticals and Viracta Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Virpax PharmaceuticalsN/AN/AN/A
Viracta TherapeuticsN/AN/AN/A

Earnings & Valuation

This table compares Virpax Pharmaceuticals and Viracta Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Virpax PharmaceuticalsN/AN/AN/AN/AN/A
Viracta TherapeuticsN/AN/AN/AN/AN/A

Summary

Viracta Therapeutics beats Virpax Pharmaceuticals on 2 of the 2 factors compared between the two stocks.

Curative Biotechnology (NASDAQ:CUBT) and Virpax Pharmaceuticals (NASDAQ:VRPX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, dividends, valuation and analyst recommendations.

Analyst Ratings

This is a breakdown of recent ratings for Curative Biotechnology and Virpax Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Curative Biotechnology0000N/A
Virpax Pharmaceuticals0000N/A

Valuation and Earnings

This table compares Curative Biotechnology and Virpax Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Curative BiotechnologyN/AN/AN/AN/AN/A
Virpax PharmaceuticalsN/AN/AN/AN/AN/A

Profitability

This table compares Curative Biotechnology and Virpax Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Curative BiotechnologyN/AN/AN/A
Virpax PharmaceuticalsN/AN/AN/A

Virpax Pharmaceuticals (NASDAQ:VRPX) and NLS Pharmaceutics (NASDAQ:NLSP) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, institutional ownership, dividends, risk, earnings, analyst recommendations and valuation.

Analyst Ratings

This is a breakdown of current ratings for Virpax Pharmaceuticals and NLS Pharmaceutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Virpax Pharmaceuticals0000N/A
NLS Pharmaceutics00303.00

NLS Pharmaceutics has a consensus price target of $10.6667, indicating a potential upside of 216.52%. Given NLS Pharmaceutics' higher probable upside, analysts clearly believe NLS Pharmaceutics is more favorable than Virpax Pharmaceuticals.

Valuation and Earnings

This table compares Virpax Pharmaceuticals and NLS Pharmaceutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Virpax PharmaceuticalsN/AN/AN/AN/AN/A
NLS PharmaceuticsN/AN/AN/AN/AN/A

Profitability

This table compares Virpax Pharmaceuticals and NLS Pharmaceutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Virpax PharmaceuticalsN/AN/AN/A
NLS PharmaceuticsN/AN/AN/A

Summary

NLS Pharmaceutics beats Virpax Pharmaceuticals on 2 of the 2 factors compared between the two stocks.


Virpax Pharmaceuticals Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
UPC
Universe Pharmaceuticals
0.0$3.19+1.6%$69.38 millionN/A0.00
VRDN
Viridian Therapeutics
1.7$17.47+0.3%$68.27 millionN/A0.00
Inhibikase Therapeutics logo
IKT
Inhibikase Therapeutics
1.0$4.75+3.4%$47.79 millionN/A0.00News Coverage
Viracta Therapeutics logo
VIRX
Viracta Therapeutics
1.5$8.21+6.5%$42.48 millionN/A0.00Analyst Revision
CUBT
Curative Biotechnology
0.0$0.11+0.0%$41.92 millionN/A0.00Gap Down
NLS Pharmaceutics logo
NLSP
NLS Pharmaceutics
1.7$3.37+0.3%$39.70 millionN/A0.00
VIRI
Virios Therapeutics
1.3$4.75+0.8%$39.57 millionN/A0.00
CMMB
Chemomab Therapeutics
1.4$16.63+2.2%$38.86 millionN/A0.00Earnings Announcement
Analyst Downgrade
VYNT
Vyant Bio
0.0$3.36+0.9%$36.98 millionN/A0.00Upcoming Earnings
News Coverage
Gap Up
MYMD
MyMD Pharmaceuticals
0.0$3.49+2.9%$29.06 millionN/A0.00Upcoming Earnings
VLON
Vallon Pharmaceuticals
0.0$3.69+0.8%$25.13 millionN/A0.00
BCTX
BriaCell Therapeutics
0.0$3.15+0.3%$18.31 millionN/A0.00
PALI
Palisade Bio
0.0$3.88+3.1%$11.19 millionN/A0.00Upcoming Earnings
High Trading Volume
ADiTx Therapeutics logo
ADTX
ADiTx Therapeutics
1.0$2.20+4.5%$0.00N/A0.00Earnings Announcement
Gap Down
Apotheca Biosciences logo
CBDC
Apotheca Biosciences
0.4$0.06+0.0%$0.00N/A0.00Gap Down
SCPS
Scopus BioPharma
1.4$5.75+3.3%$0.00N/A0.00
VERA
Vera Therapeutics
0.0$12.25+6.1%$0.00N/A0.00High Trading Volume
This page was last updated on 5/17/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.